ME02643B - Formulacija i metod obložene tablete - Google Patents
Formulacija i metod obložene tableteInfo
- Publication number
- ME02643B ME02643B MEP-2016-213A MEP21316A ME02643B ME 02643 B ME02643 B ME 02643B ME P21316 A MEP21316 A ME P21316A ME 02643 B ME02643 B ME 02643B
- Authority
- ME
- Montenegro
- Prior art keywords
- coating layer
- coating
- tablet
- polymer
- coated tablet
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims 8
- 238000009472 formulation Methods 0.000 title claims 7
- 238000000034 method Methods 0.000 title claims 3
- 239000011247 coating layer Substances 0.000 claims 23
- 239000004372 Polyvinyl alcohol Substances 0.000 claims 12
- 229920001688 coating polymer Polymers 0.000 claims 12
- 229920002451 polyvinyl alcohol Polymers 0.000 claims 12
- 239000004014 plasticizer Substances 0.000 claims 11
- 229920000642 polymer Polymers 0.000 claims 9
- 150000003839 salts Chemical class 0.000 claims 7
- QGJUIPDUBHWZPV-SGTAVMJGSA-N saxagliptin Chemical compound C1C(C2)CC(C3)CC2(O)CC13[C@H](N)C(=O)N1[C@H](C#N)C[C@@H]2C[C@@H]21 QGJUIPDUBHWZPV-SGTAVMJGSA-N 0.000 claims 7
- 229960004937 saxagliptin Drugs 0.000 claims 7
- 108010033693 saxagliptin Proteins 0.000 claims 7
- 239000010410 layer Substances 0.000 claims 5
- 229940068196 placebo Drugs 0.000 claims 5
- 239000000902 placebo Substances 0.000 claims 5
- 239000011253 protective coating Substances 0.000 claims 5
- 239000003814 drug Substances 0.000 claims 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims 4
- 239000003795 chemical substances by application Substances 0.000 claims 3
- 229940079593 drug Drugs 0.000 claims 3
- 238000001035 drying Methods 0.000 claims 3
- 230000001737 promoting effect Effects 0.000 claims 3
- 229920002785 Croscarmellose sodium Polymers 0.000 claims 2
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims 2
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims 2
- 239000011248 coating agent Substances 0.000 claims 2
- 238000000576 coating method Methods 0.000 claims 2
- 229960001681 croscarmellose sodium Drugs 0.000 claims 2
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 claims 2
- 235000019359 magnesium stearate Nutrition 0.000 claims 2
- 229940016286 microcrystalline cellulose Drugs 0.000 claims 2
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims 2
- 239000008108 microcrystalline cellulose Substances 0.000 claims 2
- WSVLPVUVIUVCRA-KPKNDVKVSA-N Alpha-lactose monohydrate Chemical compound O.O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O WSVLPVUVIUVCRA-KPKNDVKVSA-N 0.000 claims 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims 1
- 239000008199 coating composition Substances 0.000 claims 1
- 239000012458 free base Substances 0.000 claims 1
- 229960001375 lactose Drugs 0.000 claims 1
- 239000008101 lactose Substances 0.000 claims 1
- 229960001021 lactose monohydrate Drugs 0.000 claims 1
- 239000000314 lubricant Substances 0.000 claims 1
- 229940057948 magnesium stearate Drugs 0.000 claims 1
- 239000000463 material Substances 0.000 claims 1
- 239000002904 solvent Substances 0.000 claims 1
- 239000000725 suspension Substances 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2886—Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
- A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Indole Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Claims (13)
1. Obložena tableta koja se sastoji od jezgra tablete i a) unutrašnjeg izolacionog oblažućeg sloja koji oblaže jezgro tablete, koji sadrži formulaciju oblažućeg polimera koja sadrži polimer na bazi polivinil alkohola (PVA) i plastifikator;b) drugog oblažućeg sloja koji sadrži lek obložen preko unutrašnjeg izolacionog oblažućeg sloja koji oblaže jezgro tablete, te drugi oblažući sloj sadrži saksagliptinili njegovu farmaceutski prihvatljivu so i formulaciju oblažućeg polimera koja sadrži polimer na bazi PVA i plastifikator; i c) spoljašnjeg zaštitnog oblažućeg sloja koji oblaže drugi oblažući sloj jezgra tablete, pri čemu pomenuti spoljašnji zaštitni oblažući sloj sadrži formulaciju oblažućeg sloja koja sadrži polimer na bazi PVA i plastifikator,te naznačena time da drugi oblažući sloj sadrži od 0.1 do 70% težinski leka i od 30 do 99.5% težinski oblažućeg polimera, bazirano na težini drugog oblažućeg sloja.
2. Obložena tableta prema patentnom zahtevu 1 naznačena time što formulacija oblažućeg polimera u drugom oblažućem sloju je bar oko 2 mg uz jezgro tablete od 200 mg, a saksagliptin ili njegova farmaceutski prihvatljiva so je bar oko 0.2 mg uz jezgro tablete od 200 mg.
3. Obložena tableta prema patentnom zahtevu 1 naznačena time što je polimer na bazi PVA u drugom oblažućem sloju identičan polimeru na bazi PVA u drugim oblažućim slojevima.
4. Obložena tableta prema patentnom zahtevu 1 naznačena time što se polimer na bazi PVA sastoji od polivinil alkohola.
5. Obložena tableta prema patentnom zahtevu 1 naznačena time što je u drugom oblažućem sloju saksagliptin ili njemu farmaceutski odgovarajuća so prisutna u količini unutar raspona od 0,2 do 140 mg a oblažući polimer je prisutan u količini unutar raspona od 2 do 140 mg, i u svakom unutrašnjem izolacionom oblažućem sloju i spoljašnjem zaštitnom oblažućem sloju, oblažući polimer je prisutan u količini u granicama od oko 1 do oko 100 mg.
6. Obložena tableta prema patentnom zahtevu 1 naznačena time što je jezgro tablete sastavljeno od jednog ili više rastvarača i opciono jednog ili više podmazivača tablete.
7. Obložena tableta prema patentnom zahtevu 6 naznačena time što se jezgro tablete sastoji od mikrokristalne celuloze, laktoza monohidrata, kroskarmeloza natrijuma i magnezijum stearata.
8. Obložena tableta prema patentnom zahtevu 1, naznačena time što se drugi oblažući sloj sastoji od plastifikatora.
9. Obložena tableta prema patentnom zahtevu 8, naznačena time što je početna tableta drugi lek u obliku tablete.
10. Obložena tableta prema patentnom zahtevu 1 koja ima sledeći sastav: Materijal placebo tablete Raspon % težine placebo jezgra tablete od 200 mg Laktoza 20 do 75%/40 do 150 mg Mikrokristalna celuloza 20 do 75%/40 do 150 mg Kroskarmeloza natrijum 2 do 10%/4 do 20 mg Magnezijum stearat 0,2 do 2%/0,4 do 4 mg Prvi unutrašnji izolacioni oblažući sloj % težine placebo jezgra tablete od 200 mg Oblažući polimer, i opciono plastifikator i opciono agensi koji podstiču protočnost 1 do 3%/2 do 6 mg Drugi oblažući sloj % težine placebo jezgra tablete od 200 mg saksagliptin (slobodna baza ili HCL so) 0,25 do 70%/0,5 do 140 mg Oblažući polimer, i opciono plastifikator i opciono agensi koji podstiču protočnost 1 do 50%/2 do 100 mg Treći spoljašnji zaštitni oblažući sloj % težine placebo jezgra tablete od 200 mg Oblažući polimer, i opciono plastifikator i opciono agensi koji podstiču protočnost i boja 1 do 5%/2 do 10 mg
11. Obložena tableta kao što je definisano u zahtevu 1 naznačena time što se za snagu od 5 mg drugi oblažući sloj sastoji od 5 mg saksagliptina ili njegove farmaceutski prihvatljive soli i 5 mg oblažućeg sloja koji je baziran na polimeru i za snagu od 2.5 mg oblažući sloj se sastoji od 2.5 mg saksagliptina ili njegove farmaceutski prihvatljive soli i 20 mg oblažućeg sloja koji je baziran na polimeru.
12. Metod za pripremanje obložene tablete prema patentnom zahtevu 1 obuhvata sledeće: a) obezbeđivanje jezgra tablete; b) obložena tableta sa formulacijom unutrašnjeg izolacionog oblažućeg sloja koja obuhvata bar jedan polimer koji je baziran na PVA i plastifikator; c) sušenje obložene tablete radi formiranja unutrašnjeg izolacionog sloja na njoj; d) oblaganje tako obložene tablete sa formulacijom drugog oblažućeg sloja koja obuhvata lek koji je saksagliptin ili njegova farmaceutski prihvatljiva so i bar jedan oblažući polimer baziran na PVA i plastifikator; e) sušenje tako obložene tablete radi formiranja drugog oblažućeg sloja na njoj; i f) oblaganje tako obložene tablete sa formulacijom trećeg spoljašnjeg zaštitnog oblažućeg sloja koja sadrži bar jedan oblažući polimer baziran na PVA i plastifikator; i g) sušenje tako obložene tablete radi formiranja obložene tablete pronalaska.
13. Postupak kao što je definisano u patentnom zahtevu 12, naznačen time što se slojevi za oblaganje primenjuju kao suspenzija polimera za oblaganje koji je baziran na PVA i plastifikatora. 4
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US57531904P | 2004-05-28 | 2004-05-28 | |
| EP10179007.9A EP2298288B2 (en) | 2004-05-28 | 2005-05-26 | Coated tablet formulation and method |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ME02643B true ME02643B (me) | 2017-06-20 |
Family
ID=34971747
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MEP-2016-145A ME02516B (me) | 2004-05-28 | 2005-05-26 | Formulacija i metod obložene tablete |
| MEP-2016-213A ME02643B (me) | 2004-05-28 | 2005-05-26 | Formulacija i metod obložene tablete |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MEP-2016-145A ME02516B (me) | 2004-05-28 | 2005-05-26 | Formulacija i metod obložene tablete |
Country Status (33)
| Country | Link |
|---|---|
| US (4) | US7951400B2 (me) |
| EP (3) | EP1753406B2 (me) |
| JP (1) | JP4901727B2 (me) |
| KR (2) | KR101290925B1 (me) |
| CN (2) | CN102895208B (me) |
| AR (2) | AR049062A1 (me) |
| AU (1) | AU2005249467B2 (me) |
| BR (1) | BRPI0510419B8 (me) |
| CA (1) | CA2568391C (me) |
| CY (2) | CY1117813T1 (me) |
| DK (2) | DK1753406T4 (me) |
| ES (3) | ES2593582T5 (me) |
| GE (1) | GEP20094639B (me) |
| HR (2) | HRP20160880T4 (me) |
| HU (2) | HUE029446T2 (me) |
| IL (2) | IL179454A (me) |
| LT (1) | LT2298288T (me) |
| ME (2) | ME02516B (me) |
| MX (1) | MXPA06013711A (me) |
| MY (1) | MY147639A (me) |
| NO (1) | NO343907B1 (me) |
| NZ (1) | NZ551591A (me) |
| PE (1) | PE20060425A1 (me) |
| PH (1) | PH12013500450A1 (me) |
| PL (2) | PL2298288T5 (me) |
| PT (2) | PT2298288T (me) |
| RS (2) | RS54929B2 (me) |
| RU (1) | RU2372894C2 (me) |
| SI (3) | SI1753406T2 (me) |
| TW (2) | TWI415635B (me) |
| UA (1) | UA88168C2 (me) |
| WO (1) | WO2005117841A1 (me) |
| ZA (1) | ZA200609541B (me) |
Families Citing this family (129)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH0487425A (ja) * | 1990-07-31 | 1992-03-19 | Fujitsu Ltd | 回線切り替え装置 |
| SI1953162T1 (sl) * | 2001-02-24 | 2012-09-28 | Boehringer Ingelheim Pharma | Ksantinski derivati, njihova priprava in njihova uporaba kot zdravila |
| US7407955B2 (en) | 2002-08-21 | 2008-08-05 | Boehringer Ingelheim Pharma Gmbh & Co., Kg | 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions |
| ATE537141T1 (de) * | 2004-02-05 | 2011-12-15 | Kyorin Seiyaku Kk | Bicycloesterderivat |
| US7501426B2 (en) | 2004-02-18 | 2009-03-10 | Boehringer Ingelheim International Gmbh | 8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions |
| TW200534879A (en) * | 2004-03-25 | 2005-11-01 | Bristol Myers Squibb Co | Coated tablet formulation and method |
| US20050256314A1 (en) * | 2004-05-04 | 2005-11-17 | Soojin Kim | Process employing controlled crystallization in forming crystals of a pharmaceutical |
| US7829720B2 (en) * | 2004-05-04 | 2010-11-09 | Bristol-Myers Squibb Company | Process for preparing atazanavir bisulfate and novel forms |
| TWI415635B (zh) | 2004-05-28 | 2013-11-21 | 必治妥施貴寶公司 | 加衣錠片調製物及製備彼之方法 |
| DE102004054054A1 (de) | 2004-11-05 | 2006-05-11 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine |
| DE102005035891A1 (de) | 2005-07-30 | 2007-02-08 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | 8-(3-Amino-piperidin-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel |
| GB0526291D0 (en) * | 2005-12-23 | 2006-02-01 | Prosidion Ltd | Therapeutic method |
| JP2009526047A (ja) * | 2006-02-09 | 2009-07-16 | テバ ファーマシューティカル インダストリーズ リミティド | モンテルカストナトリウムの安定な医薬製剤 |
| US7915427B2 (en) * | 2006-03-08 | 2011-03-29 | Kyorin Pharmaceuticals Co., Ltd. | Process for producing aminoacetyl pyrrolidine carbonitrile derivative and intermediate for production thereof |
| BRPI0711558A2 (pt) | 2006-05-04 | 2011-11-08 | Boeringer Ingelheim Internat Gmbh | polimorfos |
| PE20080251A1 (es) | 2006-05-04 | 2008-04-25 | Boehringer Ingelheim Int | Usos de inhibidores de dpp iv |
| EP1852108A1 (en) * | 2006-05-04 | 2007-11-07 | Boehringer Ingelheim Pharma GmbH & Co.KG | DPP IV inhibitor formulations |
| US20070172525A1 (en) * | 2007-03-15 | 2007-07-26 | Ramesh Sesha | Anti-diabetic combinations |
| US20080064701A1 (en) * | 2007-04-24 | 2008-03-13 | Ramesh Sesha | Anti-diabetic combinations |
| TW200904405A (en) | 2007-03-22 | 2009-02-01 | Bristol Myers Squibb Co | Pharmaceutical formulations containing an SGLT2 inhibitor |
| JPWO2008114857A1 (ja) * | 2007-03-22 | 2010-07-08 | 杏林製薬株式会社 | アミノアセチルピロリジンカルボニトリル誘導体の製造方法 |
| PE20090696A1 (es) * | 2007-04-20 | 2009-06-20 | Bristol Myers Squibb Co | Formas cristalinas de saxagliptina y procesos para preparar las mismas |
| KR20100033378A (ko) * | 2007-06-22 | 2010-03-29 | 브리스톨-마이어스 스큅 컴퍼니 | 아타자나비르를 함유하는 정제 조성물 |
| PL2170292T3 (pl) * | 2007-06-22 | 2014-06-30 | Bristol Myers Squibb Holdings Ireland | Tabletkowane kompozycje zawierające atazanawir |
| DE602008005462D1 (de) * | 2007-06-22 | 2011-04-21 | Bristol Myers Squibb Co | Tablettierte atazanavirhaltige zusammensetzungen |
| CN101795674A (zh) * | 2007-06-22 | 2010-08-04 | 百时美施贵宝公司 | 含有阿扎那韦的压片组合物 |
| JP5623275B2 (ja) * | 2007-07-31 | 2014-11-12 | カーギル インコーポレイテッド | 直接打錠可能なデキストロース |
| CN105534936B (zh) * | 2007-08-13 | 2020-07-31 | Ohemo 生命科学股份有限公司 | 抗滥用药物、使用方法和制备方法 |
| PE20090938A1 (es) | 2007-08-16 | 2009-08-08 | Boehringer Ingelheim Int | Composicion farmaceutica que comprende un derivado de benceno sustituido con glucopiranosilo |
| US8551524B2 (en) * | 2008-03-14 | 2013-10-08 | Iycus, Llc | Anti-diabetic combinations |
| PE20140960A1 (es) | 2008-04-03 | 2014-08-15 | Boehringer Ingelheim Int | Formulaciones que comprenden un inhibidor de dpp4 |
| IT1393244B1 (it) * | 2008-07-18 | 2012-04-12 | Universita' Degli Studi Di Milano | Sistema per il rilascio al colon di farmaci suscettibili di degradazione enzimatica e/o scarsamente assorbiti nel tratto gastrointestinale |
| UY32030A (es) | 2008-08-06 | 2010-03-26 | Boehringer Ingelheim Int | "tratamiento para diabetes en pacientes inapropiados para terapia con metformina" |
| BRPI0916997A2 (pt) | 2008-08-06 | 2020-12-15 | Boehringer Ingelheim International Gmbh | Inibidor de dpp-4 e seu uso |
| JP5476305B2 (ja) * | 2008-08-07 | 2014-04-23 | 杏林製薬株式会社 | ビシクロ［２．２．２］オクチルアミン誘導体の製造方法 |
| AU2009282376A1 (en) * | 2008-08-12 | 2010-02-18 | Inspirion Delivery Technologies, Llc | Pharmaceutical compositions configured to deter dosage form splitting |
| US20110152342A1 (en) * | 2008-08-14 | 2011-06-23 | Hiroshi Uchida | Stabilized pharmaceutical composition |
| KR101657960B1 (ko) | 2008-08-15 | 2016-09-20 | 베링거 인겔하임 인터내셔날 게엠베하 | Ｆａｂ-관련 질환의 치료에 사용하기 위한 푸린 유도체 |
| AU2009290911A1 (en) | 2008-09-10 | 2010-03-18 | Boehringer Ingelheim International Gmbh | Combination therapy for the treatment of diabetes and related conditions |
| US20200155558A1 (en) | 2018-11-20 | 2020-05-21 | Boehringer Ingelheim International Gmbh | Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug |
| DE102008059206A1 (de) | 2008-11-27 | 2010-06-10 | Bayer Schering Pharma Aktiengesellschaft | Pharmazeutische Darreichungsform enthaltend Nifedipin oder Nisoldipin und einen Angiotensin-II Antagonisten und/oder ein Diuretikum |
| EP2382216A1 (en) | 2008-12-23 | 2011-11-02 | Boehringer Ingelheim International GmbH | Salt forms of organic compound |
| AR074990A1 (es) | 2009-01-07 | 2011-03-02 | Boehringer Ingelheim Int | Tratamiento de diabetes en pacientes con un control glucemico inadecuado a pesar de la terapia con metformina |
| AR075204A1 (es) | 2009-01-29 | 2011-03-16 | Boehringer Ingelheim Int | Inhibidores de dpp-4 y composiciones farmaceuticas que los comprenden, utiles para tratar enfermedades metabolicas en pacientes pediatricos, particularmente diabetes mellitus tipo 2 |
| WO2010092163A2 (en) | 2009-02-13 | 2010-08-19 | Boehringer Ingelheim International Gmbh | Antidiabetic medications |
| MX339194B (es) | 2009-02-13 | 2016-05-16 | Boehringer Ingelheim Int | Composicion farmaceutica que comprende un inhibidor de sglt2, un inhibidor de dpp-iv y opcionalmente otro agente antidiabetico, y usos de la misma. |
| KR20110135411A (ko) | 2009-03-27 | 2011-12-16 | 브리스톨-마이어스 스큅 컴퍼니 | Ｄｐｐ-ｉｖ 억제제로 주요 유해 심장혈관 이벤트를 예방하는 방법 |
| JPWO2010110436A1 (ja) | 2009-03-27 | 2012-10-04 | 杏林製薬株式会社 | 塩基性添加剤を含有するマトリックス型徐放性製剤 |
| JP6088245B2 (ja) * | 2009-04-09 | 2017-03-01 | サンド・アクチエンゲゼルシヤフト | サクサグリプチンの結晶形態 |
| CN102711739B (zh) | 2009-11-13 | 2015-12-16 | 阿斯利康(瑞典)有限公司 | 双层片剂 |
| CA3002948C (en) * | 2009-11-13 | 2020-10-27 | Astrazeneca Uk Limited | Immediate release tablet formulations |
| EA034869B1 (ru) | 2009-11-27 | 2020-03-31 | Бёрингер Ингельхайм Интернациональ Гмбх | Лечение генотипированных пациентов с диабетом ингибиторами дпп-4, такими как линаглиптин |
| JP2013522279A (ja) | 2010-03-18 | 2013-06-13 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 糖尿病及び関連状態の治療で用いるｇｐｒ１１９作動薬とｄｄｐ−ｉｖ阻害薬リナグリプチンの組合せ |
| CN102210693B (zh) * | 2010-04-10 | 2013-10-09 | 山东新华制药股份有限公司 | 一种阿司匹林和双嘧达莫多层片的制备方法 |
| MX341025B (es) | 2010-05-05 | 2016-08-04 | Boehringer Ingelheim Int Gmbh * | Terapia de combinacion. |
| US8501960B2 (en) | 2010-05-05 | 2013-08-06 | Assia Chemical Industries Ltd. | Saxagliptin intermediates, saxagliptin polymorphs, and processes for preparation thereof |
| PH12012502524A1 (en) | 2010-06-24 | 2014-02-10 | Boehringer Ingelheim Int | Diabetes therapy |
| WO2012017028A1 (en) | 2010-08-06 | 2012-02-09 | Sandoz Ag | A novel crystalline compound comprising saxagliptin and phosphoric acid |
| EP2601176A1 (en) | 2010-08-06 | 2013-06-12 | Sandoz AG | Novel salts of saxagrliptin with organic di-acids |
| CN103370064A (zh) | 2010-09-03 | 2013-10-23 | 百时美施贵宝公司 | 使用水溶性抗氧化剂的药物制剂 |
| US8410288B2 (en) | 2010-10-04 | 2013-04-02 | Teva Pharmaceutical Industries Ltd. | Polymorphs of Saxagliptin hydrochloride and processes for preparing them |
| MX366925B (es) | 2010-11-04 | 2019-07-31 | Albireo Ab | Inhibidores de ibat para el tratamiento de enfermedades hepaticas. |
| US9034883B2 (en) | 2010-11-15 | 2015-05-19 | Boehringer Ingelheim International Gmbh | Vasoprotective and cardioprotective antidiabetic therapy |
| CN102086172A (zh) * | 2011-01-13 | 2011-06-08 | 廖国超 | 沙格列汀的药用盐及其制备方法 |
| AU2012212448B9 (en) * | 2011-02-01 | 2015-06-25 | Astrazeneca Uk Limited | Pharmaceutical formulations including an amine compound |
| EP3517539B1 (en) | 2011-07-15 | 2022-12-14 | Boehringer Ingelheim International GmbH | Substituted dimeric quinazoline derivative, its preparation and its use in pharmaceutical compositions for the treatment of type i and ii diabetes |
| KR20140057604A (ko) | 2011-08-12 | 2014-05-13 | 베링거잉겔하임베트메디카게엠베하 | 고양잇과 동물의 심부전을 치료 및 예방하는 방법에 사용하기 위한 퍼니 전류 억제제 |
| EP2753328A1 (en) | 2011-09-07 | 2014-07-16 | Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi | Dpp-iv inhibitor formulations |
| US9446000B2 (en) | 2011-09-08 | 2016-09-20 | Masdar Institute Of Science And Technology | Cellulosic gel material as a pharmaceutical excipient |
| PL2578208T3 (pl) | 2011-10-06 | 2014-10-31 | Sanovel Ilac Sanayi Ve Ticaret As | Stałe formulacje dawkowane inhibitora DPP-IV |
| WO2013106526A1 (en) | 2012-01-10 | 2013-07-18 | Teva Pharmaceutical Industries Ltd. | Saxagliptin parmaceutical formulations |
| WO2013130785A2 (en) | 2012-03-01 | 2013-09-06 | Bristol-Myers Squibb Company | Extended release pharmaceutical formulations of water-soluble active pharmaceutical ingredients and methods for making the same |
| US9555001B2 (en) | 2012-03-07 | 2017-01-31 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition and uses thereof |
| WO2013167453A1 (en) | 2012-05-07 | 2013-11-14 | Bayer Pharma Aktiengesellschaft | Process for manufacturing a pharmaceutical dosage form comprising nifedipine and candesartan cilexetil |
| JP6224084B2 (ja) | 2012-05-14 | 2017-11-01 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 糸球体上皮細胞関連障害及び／又はネフローゼ症候群の治療に用いるｄｐｐ−４阻害薬としてのキサンチン誘導体 |
| US20130303554A1 (en) | 2012-05-14 | 2013-11-14 | Boehringer Ingelheim International Gmbh | Use of a dpp-4 inhibitor in sirs and/or sepsis |
| WO2013174767A1 (en) | 2012-05-24 | 2013-11-28 | Boehringer Ingelheim International Gmbh | A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference |
| WO2013179307A2 (en) * | 2012-05-29 | 2013-12-05 | Mylan Laboratories Limited | Stabilized pharmaceutical compositions of saxagliptin |
| WO2014030051A1 (en) | 2012-08-23 | 2014-02-27 | Aurobindo Pharma Limited | Stable pharmaceutical compositions comprising saxagliptin |
| WO2014065427A1 (ja) * | 2012-10-26 | 2014-05-01 | 株式会社 三和化学研究所 | アナグリプチン含有固形製剤 |
| WO2014096983A1 (en) | 2012-12-21 | 2014-06-26 | Wockhardt Limited | Stable pharmaceutical compositions of saxagliptin or salts thereof |
| WO2014096982A1 (en) | 2012-12-21 | 2014-06-26 | Wockhardt Limited | Stable pharmaceutical compositions of saxagliptin or salts thereof |
| US20140275038A1 (en) | 2013-03-15 | 2014-09-18 | Inspirion Delivery Technologies, Llc | Abuse deterrent compositions and methods of use |
| WO2014193528A1 (en) * | 2013-04-29 | 2014-12-04 | Anovel Pharmaceuticals, Llc | Amorphous dosage forms and methods |
| CN103316056B (zh) * | 2013-06-24 | 2015-07-08 | 江苏鹏鹞药业有限公司 | 一种板蓝根包衣分散片及其制备方法 |
| WO2015071887A1 (en) | 2013-11-18 | 2015-05-21 | Ranbaxy Laboratories Limited | Oral pharmaceutical compositions of saxagliptin |
| WO2015071889A1 (en) | 2013-11-18 | 2015-05-21 | Ranbaxy Laboratories Limited | Oral compositions of saxagliptin |
| CA2933202C (en) | 2014-01-21 | 2022-05-31 | Jason Teckoe | Immediate release film coatings containing medium chain glycerides and substrates coated therewith |
| US9526728B2 (en) | 2014-02-28 | 2016-12-27 | Boehringer Ingelheim International Gmbh | Medical use of a DPP-4 inhibitor |
| CA2952406A1 (en) * | 2014-06-25 | 2015-12-30 | Ea Pharma Co., Ltd. | Solid formulation and method for preventing or reducing coloration thereof |
| US10729685B2 (en) | 2014-09-15 | 2020-08-04 | Ohemo Life Sciences Inc. | Orally administrable compositions and methods of deterring abuse by intranasal administration |
| CN105520913B (zh) * | 2014-09-28 | 2020-06-23 | 石药集团中奇制药技术（石家庄）有限公司 | 一种包含沙格列汀的微丸、其用途及其制备方法 |
| CN105497023B (zh) * | 2014-10-15 | 2021-05-25 | 北京福元医药股份有限公司 | 一种沙格列汀药物制剂 |
| EP3012252A1 (en) | 2014-10-24 | 2016-04-27 | Ferring BV | Crystal modifications of elobixibat |
| CN104557943B (zh) * | 2014-12-23 | 2017-05-03 | 扬子江药业集团四川海蓉药业有限公司 | 一种维格列汀杂质的制备方法 |
| CN105796503B (zh) * | 2014-12-30 | 2019-05-07 | 深圳翰宇药业股份有限公司 | 一种沙格列汀微丸及其制剂 |
| CN104672243B (zh) * | 2015-02-10 | 2017-09-22 | 华润赛科药业有限责任公司 | 维格列汀降解杂质的制备方法 |
| US20160287573A1 (en) | 2015-04-02 | 2016-10-06 | Theravance Biopharma R&D Ip, Llc | Combination dosage form of a mu opioid receptor antagonist and an opioid agent |
| CN106176661B (zh) * | 2015-04-29 | 2019-02-01 | 四川科伦药物研究院有限公司 | 一种沙格列汀或其盐的胶囊及其制备方法 |
| TWI804919B (zh) * | 2015-06-30 | 2023-06-11 | 美商建南德克公司 | 含藥物之立即釋放錠劑及形成該錠劑的方法 |
| CN106924207A (zh) * | 2015-12-31 | 2017-07-07 | 深圳翰宇药业股份有限公司 | 一种维格列汀片剂及其制备方法 |
| CA3011595C (en) | 2016-02-09 | 2024-01-02 | Albireo Ab | Cholestyramine pellets and methods for preparation thereof |
| CN108601744B (zh) | 2016-02-09 | 2022-01-04 | 阿尔比里奥公司 | 口服考来烯胺制剂及其用途 |
| JP6954927B2 (ja) | 2016-02-09 | 2021-10-27 | アルビレオ・アクチボラグ | 経口コレスチラミン製剤及びその使用 |
| CN109310697A (zh) | 2016-06-10 | 2019-02-05 | 勃林格殷格翰国际有限公司 | 利格列汀和二甲双胍的组合 |
| CN111032019B (zh) | 2017-08-09 | 2022-07-05 | 阿尔比里奥公司 | 考来烯胺颗粒、口服考来烯胺制剂及其用途 |
| CN108822820B (zh) * | 2018-05-22 | 2020-11-03 | 东莞理工学院 | 一种隔离型水合物动力学抑制胶囊及其制备方法与应用 |
| JP7391048B2 (ja) | 2018-06-05 | 2023-12-04 | アルビレオ・アクチボラグ | ベンゾチア（ジ）アゼピン化合物及び胆汁酸モジュレータとしてのそれらの使用 |
| KR20210024033A (ko) | 2018-06-20 | 2021-03-04 | 알비레오 에이비 | 오데빅시바트의 약학 제제 |
| US11801226B2 (en) | 2018-06-20 | 2023-10-31 | Albireo Ab | Pharmaceutical formulation of odevixibat |
| US11007142B2 (en) | 2018-08-09 | 2021-05-18 | Albireo Ab | Oral cholestyramine formulation and use thereof |
| US11549878B2 (en) | 2018-08-09 | 2023-01-10 | Albireo Ab | In vitro method for determining the adsorbing capacity of an insoluble adsorbant |
| US10722457B2 (en) | 2018-08-09 | 2020-07-28 | Albireo Ab | Oral cholestyramine formulation and use thereof |
| WO2020098904A1 (en) | 2018-11-12 | 2020-05-22 | Pharmaceutical Oriented Services Ltd | Dosage form containing metformin and a dipeptidyl peptidase iv inhibitor |
| CN113453753B (zh) | 2019-02-06 | 2024-07-23 | 阿尔比里奥公司 | 苯并硫氮杂环庚三烯化合物及其用作胆汁酸调节剂的用途 |
| SG11202108566VA (en) | 2019-02-06 | 2021-09-29 | Albireo Ab | Benzothiadiazepine compounds and their use as bile acid modulators |
| CN109999006A (zh) * | 2019-04-28 | 2019-07-12 | 江苏豪森药业集团有限公司 | 沙格列汀包衣片及其制备方法 |
| CA3158181A1 (en) | 2019-12-04 | 2021-06-10 | Albireo Ab | Benzothia(di)azepine compounds and their use as bile acid modulators |
| JP7665621B2 (ja) | 2019-12-04 | 2025-04-21 | アルビレオ・アクチボラグ | ベンゾチアゼピン化合物及び胆汁酸モジュレータとしてのそれらの使用 |
| CA3158195A1 (en) | 2019-12-04 | 2021-06-10 | Per-Goran Gillberg | Benzothia(di)azepine compounds and their use as bile acid modulators |
| CN114786772B (zh) | 2019-12-04 | 2024-04-09 | 阿尔比里奥公司 | 苯并硫杂(二)氮杂环庚三烯化合物及其作为胆汁酸调节剂的用途 |
| WO2021110885A1 (en) | 2019-12-04 | 2021-06-10 | Albireo Ab | Benzothiadiazepine compounds and their use as bile acid modulators |
| JP7514121B2 (ja) | 2020-06-23 | 2024-07-10 | 沢井製薬株式会社 | サキサグリプチン含有製剤及びその製造方法 |
| ES3002777T3 (en) | 2020-08-03 | 2025-03-07 | Albireo Ab | Benzothia(di)azepine compounds and their use as bile acid modulators |
| AU2021379076A1 (en) | 2020-11-12 | 2023-06-08 | Albireo Ab | Odevixibat for treating progressive familial intrahepatic cholestasis (pfic) |
| BR112023010799A2 (pt) | 2020-12-04 | 2023-10-03 | Albireo Ab | Compostos de benzotia(di)azepina e seus usos como moduladores de ácidos biliares |
| JP2022135147A (ja) * | 2021-03-04 | 2022-09-15 | 日医工株式会社 | サキサグリプチン含有錠剤 |
| CN117412955A (zh) | 2021-06-03 | 2024-01-16 | 阿尔比里奥公司 | 苯并硫杂(二)氮杂环庚三烯化合物及其作为胆汁酸调节剂的用途 |
| KR20220165346A (ko) | 2021-06-08 | 2022-12-15 | 동아에스티 주식회사 | 에보글립틴의 안정성이 개선된 제제 |
Family Cites Families (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3696188A (en) * | 1971-06-16 | 1972-10-03 | Schering Corp | Laminated tablets |
| DE3403329A1 (de) * | 1984-02-01 | 1985-08-01 | Horst Dr. 4019 Monheim Zerbe | Pharmazeutisches produkt in form von pellets mit kontinuierlicher, verzoegerter wirkstoffabgabe |
| JPS6186211A (ja) | 1984-10-04 | 1986-05-01 | 日本碍子株式会社 | セラミックス複合構造体及びその製造法 |
| FR2623810B2 (fr) | 1987-02-17 | 1992-01-24 | Sanofi Sa | Sels de l'alpha-(tetrahydro-4,5,6,7 thieno(3,2-c) pyridyl-5) (chloro-2 phenyl) -acetate de methyle dextrogyre et compositions pharmaceutiques en contenant |
| US5158777A (en) | 1990-02-16 | 1992-10-27 | E. R. Squibb & Sons, Inc. | Captopril formulation providing increased duration of activity |
| CA2068402C (en) | 1991-06-14 | 1998-09-22 | Michael R. Hoy | Taste mask coatings for preparation of chewable pharmaceutical tablets |
| US5428048A (en) | 1993-11-08 | 1995-06-27 | American Home Products Corporation | Aryl-N-hydroxyureas as inhibitors of 5-lipoxygenase and anto-arteriosclerotic agents |
| GB9407386D0 (en) | 1994-04-14 | 1994-06-08 | Smithkline Beecham Plc | Pharmaceutical formulation |
| TW483763B (en) * | 1994-09-02 | 2002-04-21 | Astra Ab | Pharmaceutical composition comprising of ramipril and dihydropyridine compound |
| US5849911A (en) | 1996-04-22 | 1998-12-15 | Novartis Finance Corporation | Antivirally active heterocyclic azahexane derivatives |
| TW522014B (en) | 1997-02-07 | 2003-03-01 | Sepracor Inc | Lactose-free, non-hygroscopic and anhydrous pharmaceutical unit dosage form containing descarboethoxyloratadine |
| GB9715896D0 (en) | 1997-07-28 | 1997-10-01 | Sca Packaging Ltd | Containers |
| US6087383A (en) | 1998-01-20 | 2000-07-11 | Bristol-Myers Squibb Company | Bisulfate salt of HIV protease inhibitor |
| US6322819B1 (en) * | 1998-10-21 | 2001-11-27 | Shire Laboratories, Inc. | Oral pulsed dose drug delivery system |
| CA2368023A1 (en) | 1999-03-22 | 2000-09-28 | Guixue Yu | Fused pyridopyridazine inhibitors of cgmp phosphodiesterase |
| US6414002B1 (en) | 1999-09-22 | 2002-07-02 | Bristol-Myers Squibb Company | Substituted acid derivatives useful as antidiabetic and antiobesity agents and method |
| TWI271192B (en) | 1999-11-11 | 2007-01-21 | Kyorin Pharmaceutical Co Ltd | Solid formulation for oral administration |
| US6569456B2 (en) * | 2000-01-13 | 2003-05-27 | Osmotica Corp. | Osmotic device containing diltiazem and an ACE inhibitor or diuretic |
| ATE385421T1 (de) * | 2000-01-21 | 2008-02-15 | Novartis Pharma Gmbh | Zusammensetzungen bestehend aus dipeptidylpeptidase-iv inhibitoren und antidiabetica |
| US6254888B1 (en) | 2000-01-28 | 2001-07-03 | Boehringer Ingelheim Pharmaceuticals, Inc. | Method for coating pharmaceutical dosage forms |
| US6395767B2 (en) | 2000-03-10 | 2002-05-28 | Bristol-Myers Squibb Company | Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase IV and method |
| IL145106A0 (en) | 2000-08-30 | 2002-06-30 | Pfizer Prod Inc | Intermittent administration of a geowth hormone secretagogue |
| US6670344B2 (en) | 2000-09-14 | 2003-12-30 | Bristol-Myers Squibb Company | Combretastatin A-4 phosphate prodrug mono- and di-organic amine salts, mono- and di- amino acid salts, and mono- and di-amino acid ester salts |
| US6867300B2 (en) | 2000-11-17 | 2005-03-15 | Bristol-Myers Squibb Company | Methods for the preparation of pyrrolotriazine compounds useful as kinase inhibitors |
| US6670334B2 (en) * | 2001-01-05 | 2003-12-30 | University Of Virginia Patent Foundation | Method and compositions for treating the inflammatory response |
| WO2002085335A1 (en) | 2001-04-18 | 2002-10-31 | Nostrum Pharmaceuticals Inc. | A novel coating for a sustained release pharmaceutical composition |
| US20030035839A1 (en) * | 2001-05-15 | 2003-02-20 | Peirce Management, Llc | Pharmaceutical composition for both intraoral and oral administration |
| AU2003201071A1 (en) | 2002-01-15 | 2003-07-30 | Ranbaxy Laboratories Limited | Stable pharmaceutical compositions comprising ace inhibitor(s) |
| KR100456833B1 (ko) | 2002-08-01 | 2004-11-10 | 주식회사 대웅 | 아목시실린 및 클라불라네이트를 함유하는 유핵정 |
| US7670624B2 (en) | 2004-01-29 | 2010-03-02 | Astella Pharma Inc. | Gastrointestinal-specific multiple drug release system |
| TW200534879A (en) | 2004-03-25 | 2005-11-01 | Bristol Myers Squibb Co | Coated tablet formulation and method |
| US7829720B2 (en) | 2004-05-04 | 2010-11-09 | Bristol-Myers Squibb Company | Process for preparing atazanavir bisulfate and novel forms |
| US20050256314A1 (en) | 2004-05-04 | 2005-11-17 | Soojin Kim | Process employing controlled crystallization in forming crystals of a pharmaceutical |
| US20050288343A1 (en) | 2004-05-19 | 2005-12-29 | Andrew Rusowicz | Process of preparing substituted carbamates and intermediates thereof |
| TWI415635B (zh) | 2004-05-28 | 2013-11-21 | 必治妥施貴寶公司 | 加衣錠片調製物及製備彼之方法 |
-
2005
- 2005-05-23 TW TW100134799A patent/TWI415635B/zh not_active IP Right Cessation
- 2005-05-23 TW TW094116772A patent/TWI354569B/zh not_active IP Right Cessation
- 2005-05-24 RS RS20160563 patent/RS54929B2/sr unknown
- 2005-05-25 US US11/137,068 patent/US7951400B2/en active Active
- 2005-05-26 KR KR1020067024818A patent/KR101290925B1/ko not_active Expired - Lifetime
- 2005-05-26 AU AU2005249467A patent/AU2005249467B2/en not_active Expired
- 2005-05-26 EP EP05756474.2A patent/EP1753406B2/en not_active Expired - Lifetime
- 2005-05-26 MX MXPA06013711A patent/MXPA06013711A/es active IP Right Grant
- 2005-05-26 SI SI200532082T patent/SI1753406T2/sl unknown
- 2005-05-26 SI SI200532082A patent/SI1753406T1/sl unknown
- 2005-05-26 CN CN201210377942.2A patent/CN102895208B/zh not_active Expired - Lifetime
- 2005-05-26 NZ NZ551591A patent/NZ551591A/en not_active IP Right Cessation
- 2005-05-26 RU RU2006146971/15A patent/RU2372894C2/ru active
- 2005-05-26 PL PL10179007T patent/PL2298288T5/pl unknown
- 2005-05-26 ES ES10179007T patent/ES2593582T5/es not_active Expired - Lifetime
- 2005-05-26 PT PT101790079T patent/PT2298288T/pt unknown
- 2005-05-26 CA CA2568391A patent/CA2568391C/en not_active Expired - Fee Related
- 2005-05-26 ME MEP-2016-145A patent/ME02516B/me unknown
- 2005-05-26 PT PT05756474T patent/PT1753406E/pt unknown
- 2005-05-26 DK DK05756474T patent/DK1753406T4/da active
- 2005-05-26 HU HUE10179007A patent/HUE029446T2/en unknown
- 2005-05-26 ES ES16166031T patent/ES2754573T3/es not_active Expired - Lifetime
- 2005-05-26 WO PCT/US2005/018692 patent/WO2005117841A1/en not_active Ceased
- 2005-05-26 EP EP16166031.1A patent/EP3078369B1/en not_active Expired - Lifetime
- 2005-05-26 CN CN2005800245879A patent/CN1988891B/zh not_active Expired - Lifetime
- 2005-05-26 SI SI200532097T patent/SI2298288T2/sl unknown
- 2005-05-26 PH PH1/2013/500450A patent/PH12013500450A1/en unknown
- 2005-05-26 DK DK10179007.9T patent/DK2298288T4/da active
- 2005-05-26 ME MEP-2016-213A patent/ME02643B/me unknown
- 2005-05-26 UA UAA200613939A patent/UA88168C2/uk unknown
- 2005-05-26 RS RS20160797A patent/RS55174B2/sr unknown
- 2005-05-26 MY MYPI20052400A patent/MY147639A/en unknown
- 2005-05-26 JP JP2007515382A patent/JP4901727B2/ja not_active Expired - Lifetime
- 2005-05-26 GE GEAP20059797A patent/GEP20094639B/en unknown
- 2005-05-26 PL PL05756474T patent/PL1753406T5/pl unknown
- 2005-05-26 HU HUE05756474A patent/HUE029039T2/en unknown
- 2005-05-26 EP EP10179007.9A patent/EP2298288B2/en not_active Expired - Lifetime
- 2005-05-26 KR KR1020127014475A patent/KR20120064141A/ko not_active Ceased
- 2005-05-26 LT LTEP10179007.9T patent/LT2298288T/lt unknown
- 2005-05-26 BR BRPI0510419A patent/BRPI0510419B8/pt not_active IP Right Cessation
- 2005-05-26 HR HRP20160880TT patent/HRP20160880T4/hr unknown
- 2005-05-26 ES ES05756474T patent/ES2582646T5/es not_active Expired - Lifetime
- 2005-05-27 AR ARP050102188A patent/AR049062A1/es not_active Application Discontinuation
- 2005-05-30 PE PE2005000601A patent/PE20060425A1/es active IP Right Grant
-
2006
- 2006-11-16 ZA ZA2006/09541A patent/ZA200609541B/en unknown
- 2006-11-21 IL IL179454A patent/IL179454A/en active IP Right Grant
- 2006-12-15 NO NO20065870A patent/NO343907B1/no unknown
-
2011
- 2011-04-26 US US13/094,379 patent/US8628799B2/en not_active Expired - Fee Related
-
2012
- 2012-02-14 IL IL218117A patent/IL218117A/en active IP Right Grant
-
2014
- 2014-01-08 US US14/150,331 patent/US9339472B2/en not_active Expired - Lifetime
- 2014-05-22 US US14/284,840 patent/US20140255486A1/en not_active Abandoned
-
2015
- 2015-02-24 AR ARP150100554A patent/AR099567A2/es unknown
-
2016
- 2016-07-19 CY CY20161100703T patent/CY1117813T1/el unknown
- 2016-09-21 HR HRP20161210TT patent/HRP20161210T4/hr unknown
- 2016-09-22 CY CY20161100945T patent/CY1118162T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20161210T4 (hr) | Formulacija obložene tablete i postupak | |
| JP2008501025A5 (me) | ||
| Conte et al. | Modulation of the dissolution profiles from Geomatrix® multi-layer matrix tablets containing drugs of different solubility | |
| CA2578626A1 (en) | Modified-release formulations of a bupropion salt | |
| US20070098746A1 (en) | Multi-layered coating technology for taste masking | |
| US8173637B2 (en) | Stabilized atypical antipsychotic formulation | |
| ES2200832T3 (es) | Formulacion de bupropion de liberacion controlada. | |
| JP2016516698A5 (me) | ||
| KR101249171B1 (ko) | 비구아나이드와 티아졸리디네디온 유도체를 함유하는 새로운 약제학적 제형 | |
| YU49236B (sh) | Višejedinični dozni oblici u tabletama koji sadrže omeprazol i jednu njegovu alkalnu so ili jedan enantiomer omeprazola ili jednu njegovu alkalnu so | |
| JP2011510024A5 (me) | ||
| HRP20190069T1 (hr) | Farmaceutske formulacije koje sadrže ccr3 antagoniste | |
| HRP20251291T1 (hr) | Formulacije (+)-2-[1-(3-etoksi-4-metoksi-fenil)-2-metansulfonil-etil]-4-acetil aminoizoindolin-1,3-diona | |
| RU2005108609A (ru) | Лекарственные формы с модифицированным высвобождением, имеющие два ядра и отверстие | |
| AU2008306846B2 (en) | Mechanical protective layer for solid dosage forms | |
| HRP20070353T3 (en) | Extended release coated minitablets of venlafaxine hydrochloride | |
| WO2008023390B1 (en) | Modified release pharmaceutical composition of bupropion hydrochloride | |
| JP5822758B2 (ja) | 速溶性防湿フィルムコーティング製剤及びその製造方法 | |
| CN104873457A (zh) | 缓释剂型 | |
| JP2020132600A (ja) | フィルムコーティング錠剤、およびその製造方法 | |
| KR101345468B1 (ko) | 졸피뎀 정제 | |
| TH75893A (th) | สูตรผสมยาเม็ดเคลือบและวิธี | |
| TH43293B (th) | สูตรผสมยาเม็ดเคลือบและวิธี | |
| JPH07252139A (ja) | 被覆軟カプセル剤 | |
| KR20160137507A (ko) | 고형 제제용의 코팅제 및 이것으로 형성된 피막 및 피복 고형 제제 |